End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8,380 KRW | +0.12% | -1.18% | -10.37% |
03-18 | Rayence Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Rayence Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2023 | CI |
Strengths
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.37% | 96.74M | - | ||
-7.03% | 14.43B | - | ||
-39.46% | 2.77B | C- | ||
-13.36% | 2.44B | - | ||
-15.28% | 1.41B | - | - | |
-.--% | 1.12B | - | - | |
+41.44% | 521M | - | ||
+87.44% | 494M | B+ | ||
+26.28% | 277M | C | ||
-7.75% | 213M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- A228850 Stock
- Ratings Rayence Co., Ltd.